Patents Assigned to Drossapharm AG
  • Publication number: 20140234396
    Abstract: The present invention provides to patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. In an external patch in which an adhesive layer containing an adhesive base and a drug are laminated with a backing, the external patch wherein the adhesive base contains 5-50% by weight of synthetic rubber polymer, 10-60% by weight of adhesive resin and 25-60% by weight of liquid paraffin, and the drug is etofenamate. According to the present invention, there is obtainable the patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation.
    Type: Application
    Filed: April 29, 2014
    Publication date: August 21, 2014
    Applicants: TEIKOKU SEIYAKU CO., LTD., DROSSAPHARM AG
    Inventors: Tomohiro ISHIMA, Hiroyuki YAMASAKI, Masahiro YAMAJI
  • Patent number: 8747885
    Abstract: The present invention provides to patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. In an external patch in which an adhesive layer containing an adhesive base and a drug are laminated with a backing, the external patch wherein the adhesive base contains 5-50% by weight of synthetic rubber polymer, 10-60% by weight of adhesive resin and 25-60% by weight of liquid paraffin, and the drug is etofenamate. According to the present invention, there is obtainable the patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: June 10, 2014
    Assignees: Teikoku Seiyaku Co., Ltd., Drossapharm AG
    Inventors: Tomohiro Ishima, Hiroyuki Yamasaki, Masahiro Yamaji
  • Patent number: 5750139
    Abstract: Sufficiently high blood benzopyrone levels cannot be achieved on oral administration of benzopyrone. From the point of view of pharmacokinetics and chronic application, the use of benzopyrone as an ointment is not optimal because the blood levels thus achievable cannot be controlled. It has now surprisingly been found that benzopyrone in a particular formulation as part of a transdermal dermal therapeutic system (TDS), after application to the skin, is released to the skin in a constant manner as a function of time and over a longer period owing to the absorption of perspiration, and that constant therapeutically effective blood and tissue levels of benzopyrone are achieved in humans, which levels are a factor of 50 higher than those following the oral administration of the same doses of benzopyrone.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: May 12, 1998
    Assignee: Drossapharm AG
    Inventors: Jurg Lutz, Henning F. Cierpka